Horizon Therapeutics shares are trading higher after the FTC paused its challenge against Amgen's proposed acquisition of the company until Sept. 18.
Portfolio Pulse from Benzinga Newsdesk
The Federal Trade Commission (FTC) has paused its challenge against Amgen's proposed acquisition of Horizon Therapeutics, causing Horizon's shares to trade higher. The challenge is paused until September 18.
August 28, 2023 | 1:10 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Horizon Therapeutics' shares are trading higher due to the FTC's pause on its challenge against Amgen's proposed acquisition of the company.
The FTC's decision to pause its challenge against Amgen's proposed acquisition of Horizon Therapeutics has led to an increase in Horizon's share price. This is because the pause could be seen as a positive sign for the acquisition to go through, which would likely be beneficial for Horizon's shareholders.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100